MedTrace Logo

Rituximab Treatment of Focal Segmental Glomerulosclerosis

NCT00550342 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)

Conditions

  • Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG

rituximab

375 mg/m2 intravenously for 4 doses

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Indiana University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Mark D Pescovitz, MD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-12-31
Completion
2009-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00550342 on ClinicalTrials.gov